Exploring how GTP metabolism affects breast cancer cell invasion
Leveraging the GTP Biosynthetic Pathway for Anti-Tumor Therapies
['FUNDING_R37'] · ROSWELL PARK CANCER INSTITUTE CORP · NIH-10983306
This study is looking at how a substance called GTP affects the spread of aggressive triple negative breast cancer cells, with the hope of finding new ways to stop the cancer from spreading in patients.
Quick facts
| Phase | ['FUNDING_R37'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | ROSWELL PARK CANCER INSTITUTE CORP (nih funded) |
| Locations | 1 site (BUFFALO, UNITED STATES) |
| Trial ID | NIH-10983306 on ClinicalTrials.gov |
What this research studies
This research investigates the role of GTP metabolism in the invasiveness of breast cancer cells, particularly focusing on triple negative breast cancer (TNBC), which is known for its aggressive nature and lack of targeted therapies. The team aims to understand how variations in GTP levels within cells can influence tumor cell behavior and promote metastasis. By utilizing innovative fluorescent reporters to visualize GTP distribution in live cells, the researchers will explore potential therapeutic strategies that could inhibit cancer spread. The ultimate goal is to develop new treatments that can effectively reduce the risk of metastasis in breast cancer patients.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with triple negative breast cancer who are seeking new treatment options.
Not a fit: Patients with non-breast cancers or those whose tumors are not triple negative may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that significantly reduce the spread of breast cancer, improving survival rates for patients.
How similar studies have performed: Previous research has shown promising results in targeting metabolic pathways in cancer, suggesting that this approach could yield significant advancements.
Where this research is happening
BUFFALO, UNITED STATES
- ROSWELL PARK CANCER INSTITUTE CORP — BUFFALO, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: BIANCHI-SMIRAGLIA, ANNA — ROSWELL PARK CANCER INSTITUTE CORP
- Study coordinator: BIANCHI-SMIRAGLIA, ANNA
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Breast Cancer, breast cancer progression, cancer cell, cancer invasiveness